Fibromyalgia Treatment Market – Size, Share,
Outlook, and Opportunity Analysis, 2018 – 2026
Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain,
fatigue, and localized tenderness affecting individuals mentally, physically, and socially.
Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown.
The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle
pain, and tender points. An individual with fibromyalgia can also have symptoms such as
headaches, poor concentration, and depression. Fibromyalgia symptoms might accumulate with
time or it can be caused by some external factors. Fibromyalgia treatments include therapy,
medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of
fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety,
pain, and fatigue.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1691
Robust pipeline of novel drugs are under late clinical trial phase for treatment of fibromyalgia
Market players are focusing on active research and development, in order to introduce new
products in the market and increase treatment options. Approval and launch of novel
fibromyalgia treatment drugs is expected to significantly support fibromyalgia treatment market
growth over the forecast period.
For instance, manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative
Med Concepts, Inc., Intec Pharma Ltd., Astellas Pharma, Inc., and others have drugs in the
pipeline indicated for the treatment of fibromyalgia.
Many such drugs are in phase 2 and phase 3 of clinical trials with commercialization potential.
For instance, Astellas Pharma, Inc. has ASP0819 in phase 2 and IMC-1 that received fast track
designation from the U.S. FDA in 2016.
The global fibromyalgia treatment market size was valued at US$ 2,778.6 Mn in 2018 and is
expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).